LexaGene Verifies CDC Monkeypox Assay Works on MiQLab System and Readies Company Should an EUA be Declared
29 August 2022 - 10:00PM
LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG)
(“LexaGene” or the “Company”), an innovative, molecular diagnostics
company that has commercialized the MiQLab® System for automated,
genetic testing, announces the System can perform the Centers for
Disease Control and Prevention (CDC) Monkeypox real-time PCR test.1
On July 23rd, the World Health Organization
declared Monkeypox a public health emergency of international
concern,2 and on August 4th, the United States government declared
the epidemic a public health emergency.3 There is concern that
back-to-school activities could result in a spike in
infections.
Monkeypox is a viral disease for which there is
no known cure. Symptoms include fever, swollen lymph nodes, and a
rash that forms blisters. Symptoms can be severe, particularly in
children, pregnant women and immunocompromised individuals.
Occasionally, Monkeypox can be deadly. There is also evidence this
virus can be spread from humans to dogs,4 prompting interest from
the veterinary community in diagnosing this disease.
Dr. Jack Regan, LexaGene’s Founder and CEO
stated, “During the COVID-19 pandemic, we advanced our Company and
our technology. The FDA has not yet declared an EUA for this
epidemic, but should one be declared, LexaGene is in position to
pursue such an authorization. The MiQLab System is a platform that
can be quickly configured to detect any new pathogen and for this
reason we continue to advance it as a solution for rapidly
detecting newly emergent pathogens at the point-of-care.”
The company is not making any expressed or
implied claims that its product has ability to eliminate, cure or
contain Monkeypox at this time. Should an EUA be declared for
Monkeypox, LexaGene’s management will take many factors into
consideration when deciding whether to pursue such an
authorization.
For more information about LexaGene and the MiQLab System,
please visit www.lexagene.com or follow us on Twitter or
LinkedIn.
About LexaGene Holdings
Inc. LexaGene
is a molecular diagnostics company that has commercialized the
MiQLab System for fast and easy detection of pathogens and other
molecular markers. The System is designed for on-site usage and
uses real-time PCR chemistry. Our customers include veterinary
hospitals and reference laboratories – as well as contract biologic
manufacturers. The MiQLab System delivers excellent sensitivity,
specificity, and breadth of detection.
The TSX Venture Exchange Inc. has in no way
passed upon the merits of the proposed transaction and has neither
approved nor disapproved the contents of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This news release contains forward-looking
information, which involves known and unknown risks, uncertainties
and other factors that may cause actual events to differ materially
from current expectation. Important factors -- including the
availability of funds, the results of financing efforts, the
success of technology development efforts, the cost to procure
critical parts, performance of the instrument, market acceptance of
the technology, regulatory acceptance, and licensing issues -- that
could cause actual results to differ materially from the Company's
expectations as disclosed in the Company's documents filed from
time to time on SEDAR (see www.sedar.com). Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
The company disclaims any intention or obligation, except to the
extent required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
1 https://www.cdc.gov/poxvirus/monkeypox/pdf/PCR-Diagnostic-Protocol-508.pdf
2
https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern
3
https://www.hhs.gov/about/news/2022/08/04/biden-harris-administration-bolsters-monkeypox-response-hhs-secretary-becerra-declares-public-health-emergency.html4
https://www.msn.com/en-in/news/other/first-known-human-to-dog-monkeypox-transmission-reported-in-france/ar-AA10Qblo#:~:text=The%20first%20known%20human-to-dog%20transmission%20of%20monkeypox%20involving,for%20isolation%20from%20pets%20and%20proper%20waste%20management
Lexagene (TSXV:LXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexagene (TSXV:LXG)
Historical Stock Chart
From Apr 2023 to Apr 2024